|
1
|
Carvalho FO, Silva ÉR, Nunes PS, Felipe FA, Ramos KPP, Ferreira LAS, Lima VNB, Shanmugam S, Oliveira AS, Guterres SS, Camargo EA, Cravalho Olivera TV, de Albuquerque Júnior RLC, de Lucca Junior W, Quintans-Júnior LJ, Araújo AAS. Effects of the solid lipid nanoparticle of carvacrol on rodents with lung injury from smoke inhalation. Naunyn Schmiedebergs Arch Pharmacol 2019; 393:445-455. [PMID: 31655855 DOI: 10.1007/s00210-019-01731-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Accepted: 09/10/2019] [Indexed: 01/13/2023]
Abstract
The aim of this present study was to evaluate the effect of solid lipid nanoparticles (SLN) containing carvacrol over the lung damage of airway smoke inhalation. The study was conducted with 30 rats subjected to smoke inhalation and divided into 5 groups such as, normal control, negative control, oxygen group, SLN alone, and SLN+CARV group. The animals were sacrificed 24 h after the induction of inhalation injury further, the tissues of larynx, trachea, and lungs were collected for the histological, hematological, myeloperoxidase, and malondialdehyde analysis. The obtained results showed that treatment with CARV+SLN minimized the inhalation injury, since it reduced malondialdehyde significantly, when compared to the negative control group and minimized the histological changes which proves the absence of pulmonary emphysema and exudate in laryngeal and tracheal lumen in the CARV+SLN-treated group. Meanwhile, the presence of lesion with chronic characteristics was observed in the negative control and oxygen groups. It is suggested that the SLN containing carvacrol minimized oxidative stress and histological damages generated from smoke inhalation in rodents.
Collapse
Affiliation(s)
- Fernanda O Carvalho
- Health Sciences Post-Graduate Program, Federal University of Sergipe, Claudio Batista St s/n, Aracaju, SE, 49060-100, Brazil
| | - Érika R Silva
- Health Sciences Post-Graduate Program, Federal University of Sergipe, Claudio Batista St s/n, Aracaju, SE, 49060-100, Brazil
| | - Paula S Nunes
- Health Sciences Post-Graduate Program, Federal University of Sergipe, Claudio Batista St s/n, Aracaju, SE, 49060-100, Brazil.
| | - Fernanda A Felipe
- Health Sciences Post-Graduate Program, Federal University of Sergipe, Claudio Batista St s/n, Aracaju, SE, 49060-100, Brazil
| | - Karen P P Ramos
- Health Sciences Post-Graduate Program, Federal University of Sergipe, Claudio Batista St s/n, Aracaju, SE, 49060-100, Brazil
| | - Luiz Augusto S Ferreira
- Health Sciences Post-Graduate Program, Federal University of Sergipe, Claudio Batista St s/n, Aracaju, SE, 49060-100, Brazil
| | - Viviane N B Lima
- Health Sciences Post-Graduate Program, Federal University of Sergipe, Claudio Batista St s/n, Aracaju, SE, 49060-100, Brazil
| | - Saravanan Shanmugam
- Health Sciences Post-Graduate Program, Federal University of Sergipe, Claudio Batista St s/n, Aracaju, SE, 49060-100, Brazil.
| | - Alan Santos Oliveira
- Health Sciences Post-Graduate Program, Federal University of Sergipe, Claudio Batista St s/n, Aracaju, SE, 49060-100, Brazil
| | - Sílvia S Guterres
- Post-Graduation Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Ipiranga Avenue 2752, Porto Alegre, RS, 90610-000, Brazil
| | - Enilton A Camargo
- Health Sciences Post-Graduate Program, Federal University of Sergipe, Claudio Batista St s/n, Aracaju, SE, 49060-100, Brazil
| | | | | | - Waldecy de Lucca Junior
- Health Sciences Post-Graduate Program, Federal University of Sergipe, Claudio Batista St s/n, Aracaju, SE, 49060-100, Brazil
| | - Lucindo José Quintans-Júnior
- Health Sciences Post-Graduate Program, Federal University of Sergipe, Claudio Batista St s/n, Aracaju, SE, 49060-100, Brazil
| | - Adriano A S Araújo
- Health Sciences Post-Graduate Program, Federal University of Sergipe, Claudio Batista St s/n, Aracaju, SE, 49060-100, Brazil
| |
Collapse
|
|
2
|
Zhao X, Liu J, Yang S, Chen C, Yin H, Li T, Wang Q, Li X, Lin Y, Cai D. Diammonium glycyrrhizinate alleviates hepatopulmonary syndrome via restoring superoxide dismutase 3 activity in rats. Eur J Pharmacol 2017; 807:144-150. [DOI: 10.1016/j.ejphar.2017.04.025] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2016] [Revised: 04/17/2017] [Accepted: 04/19/2017] [Indexed: 02/07/2023]
|
|
4
|
Nacif LS, Andraus W, Kubrusly MS, Kubrusly FS, Gebara VCBC, Ishizawa A, D'Albuquerque LAC. Surfactant protein A is decreased in the lung of rats with hepatopulmonary syndrome. Acta Cir Bras 2015; 29:573-8. [PMID: 25252203 DOI: 10.1590/s0102-8650201400150004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2014] [Accepted: 07/21/2014] [Indexed: 11/22/2022] Open
Abstract
PURPOSE To evaluate surfactant protein A levels in an hepatopulmonary syndrome rat model. To date, there have been no studies aimed at evaluating surfactant levels in the setting of cirrhosis or hepatopulmonary syndrome. METHODS A total of 35 rats were divided into control, sham, and experimental HPS groups. We evaluated surfactant protein A levels in rats and the experimental model designed to induce hepatopulmonary syndrome was common bile duct ligation. Statistical analysis was performed using GraphPad Prism Software(r). Differences were considered statistically significant when p<0.05. RESULTS Lung homogenate of surfactant protein A levels were lower in the experimental hepatopulmonary syndrome and sham groups in comparison to the control group (p<0.05). Serum SP-A levels were the same in experimental hepatopulmonary syndrome and control groups but decreased in the sham group compared with the experimental groups (p<0.05). Myeloperoxidase activity was higher in the experimental hepatopulmonary syndrome group than the other two groups (p<0.05). CONCLUSION Surfactant protein A is present in experimental hepatopulmonary syndrome and leads to an imbalance between serum and pulmonary levels due to systemic inflammatory response.
Collapse
Affiliation(s)
| | - Wellington Andraus
- Department of Gastroenterology, School of Medicine, USP, Sao Paulo, SP, Brazil
| | | | | | | | - Andrea Ishizawa
- Biotechnology Center, Butantan Institute, Sao Paulo, SP, Brazil
| | | |
Collapse
|
|
5
|
Nacif LS, Andraus W, Kubrusly MS, Molan N, Chaib E, D'Albuquerque LAC. Myeloperoxidase activity is increased in hepatopulmonary syndrome in rats. ABCD-ARQUIVOS BRASILEIROS DE CIRURGIA DIGESTIVA 2014; 26:293-5. [PMID: 24510037 DOI: 10.1590/s0102-67202013000400008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/19/2013] [Accepted: 07/23/2013] [Indexed: 11/22/2022]
Abstract
BACKGROUND Hepatopulmonary syndrome is formed by a triad of liver disease, intrapulmonary vascular dilatation and changes in blood gases. Its pathogenesis is not well defined, but it is speculated that a combination of factors, such as the imbalance of endothelin receptor responses, pulmonary microvascular remodeling, and genetic predisposition, leads to bacterial translocation and intrapulmonary vascular dilatation. AIM To evaluate the myeloperoxidase activity in hepatopulmonary syndrome in rat model. METHOD Twenty-nine rats were divided into control, sham and experimental hepatopulmonary syndrome groups. Was evaluated the myeloperoxidase activity and the experimental model used to induce hepatopulmonary syndrome was common bile duct ligation. RESULTS The myeloperoxidase activity levels were significantly increased in the common bile duct ligation group as compared with the other groups. Myeloperoxidase activity was higher in the common bile duct ligation group than control group (p<0.05) and than sham group (p<0.05). CONCLUSION The myeloperoxidase activity is increased in experimental hepatopulmonary syndrome in rats.
Collapse
|